Key Takeaways TEM projects strong 2025 sales growth while ILMN expects steadier earnings gains and margin expansion. Tempus is advancing diagnostics like xM and PurIST while expanding collaborations with pharma partners. ILMN strengthened its oncology lineup with TruSight Oncology 500 upgrades and broader pharma partnerships. Investors are showing growing interest in the rapidly expanding Precision Oncology market, which is expected to witness a compound annual growth rate (CAGR) of 8% between 2025 and 2030 ...

Key Takeaways Tempus AI gained FDA clearance for its RNA sequencing-based xR IVD device. TEM's xR IVD detects gene rearrangements in tumor tissues from solid malignancies.The device bolsters Tempus AI's role in oncology research and drug development. RNA sequencing provides a comprehensive view of biological information, offering deeper insights into disease mechanisms, including improved fusion detection. As a powerful tool in research and development, RNA analysis helps identify molecular pathways and ne ...